Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (391-400 of 1,126) with videos related to

Pageof 113
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancerJochen Walz, Andrea Gallina, Fred Saad, et al.
Journal of Surgical Oncology|August 20, 2020
Assessment of other-cause mortality in localized renal cell carcinoma patients within 15 years: A population-based analysisAngela Pecoraro, Sophie Knipper, Carlotta Palumbo, et al.
Urologic Oncology|July 31, 2021
The effect of race on stage at presentation and survival in upper tract urothelial carcinomaClaudia Collà Ruvolo, Mike Wenzel, Luigi Nocera, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|September 14, 2013
CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 updateFred Saad, Sebastien Hotte, Charles Catton, et al.
The Journal of Urology|February 9, 2023
Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical TrialMaha Hussain, Cora N Sternberg, Eleni Efstathiou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2016
Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive AgentsAllan Lipton, Matthew R Smith, Karim Fizazi, et al.
European Urology Focus|December 6, 2024
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: An Updated Network Meta-analysis Including ARANOTE DataBenedikt Hoeh, Mike Wenzel, Zhe Tian, et al.
Future Oncology (London, England)|August 16, 2023
Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?Maha Hussain, Cora N Sternberg, Eleni Efstathiou, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2019
Trends and Social Barriers for Inpatient Palliative Care in Patients With Metastatic Bladder Cancer Receiving Critical Care TherapiesElio Mazzone, Sophie Knipper, Francesco A Mistretta, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 4, 2021
Stage and cancer-specific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American population-based studyClaudia Collà Ruvolo, Christoph Würnschimmel, Luigi Nocera, et al.
Pageof 113

Showing results (391-400 of 1,126) with videos related to

Sort By:
Pageof 113
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancerJochen Walz, Andrea Gallina, Fred Saad, et al.
Journal of Surgical Oncology|August 20, 2020
Assessment of other-cause mortality in localized renal cell carcinoma patients within 15 years: A population-based analysisAngela Pecoraro, Sophie Knipper, Carlotta Palumbo, et al.
Urologic Oncology|July 31, 2021
The effect of race on stage at presentation and survival in upper tract urothelial carcinomaClaudia Collà Ruvolo, Mike Wenzel, Luigi Nocera, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|September 14, 2013
CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 updateFred Saad, Sebastien Hotte, Charles Catton, et al.
The Journal of Urology|February 9, 2023
Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical TrialMaha Hussain, Cora N Sternberg, Eleni Efstathiou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2016
Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive AgentsAllan Lipton, Matthew R Smith, Karim Fizazi, et al.
European Urology Focus|December 6, 2024
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: An Updated Network Meta-analysis Including ARANOTE DataBenedikt Hoeh, Mike Wenzel, Zhe Tian, et al.
Future Oncology (London, England)|August 16, 2023
Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?Maha Hussain, Cora N Sternberg, Eleni Efstathiou, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2019
Trends and Social Barriers for Inpatient Palliative Care in Patients With Metastatic Bladder Cancer Receiving Critical Care TherapiesElio Mazzone, Sophie Knipper, Francesco A Mistretta, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 4, 2021
Stage and cancer-specific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American population-based studyClaudia Collà Ruvolo, Christoph Würnschimmel, Luigi Nocera, et al.
Pageof 113